Xenon Pharmaceuticals Inc (XENE) — Analysis Summary
Xenon Pharmaceuticals Inc (XENE) has a market cap of $5.64B with year-over-year revenue growth of -20.5%. Net margin stands at -4612.1%. The stock trades at a P/E ratio of -13.8.
Key Takeaways
- Revenue changed -20.5% year-over-year
- Net margin of -4612.1%
- P/E ratio of -13.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, XENE posted revenue growth of -20.5% and trades at a P/E of -13.8.
Xenon Pharmaceuticals Inc (XENE)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Revenue fell 100.0% vs the prior period.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
370
Headquarters
BURNABY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.